Gankyrin plays an essential role in estrogen-driven and GPR30-mediated endometrial carcinoma cell proliferation via the PTEN/PI3K/AKT signaling pathway

Cancer Letters

Volumn 339, Issue 2, 2013, Pages 279-287

  Zhang, Jiawen ^a   Yang, Yongbin ^a   Zhang, Zhenbo ^a   He, Yinyan ^a   Liu, Zhiqiang ^b   Yu, Yinhua ^b,c   Wu, Sufang ^a   Cai, Bin ^a   Feng, Youji ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

^c OBSTETRICS AND GYNECOLOGY HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Endometrial carcinoma; Estrogen; Gankyrin; Proliferation; PTEN

Indexed keywords

ESTROGEN; G PROTEIN COUPLED RECEPTOR 30; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SMALL INTERFERING RNA;

ADULT; ARTICLE; CANCER CELL; CANCER GRADING; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIUM CARCINOMA; FEMALE; GANKYRIN GENE; GENE; GENE FUNCTION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ENDOMETRIAL CARCINOMA; ESTROGEN; GANKYRIN; PROLIFERATION; PTEN;

ADULT; AGED; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84883800660     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.10.037     Document Type: Article

References (43)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Bokhman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983, 15:10-17.
3. Lax S.F., Pizer E.S., Ronnett B.M., Kurman R.J. Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation. Human Pathol. 1998, 29:924-931.
4. Dedes K.J., Wetterskog D., Ashworth A., Kaye S.B., Reis-Filho J.S. Emerging therapeutic targets in endometrial cancer. Nat. Rev. Clin. Oncol. 2011, 8:261-271.
5. Alvarez T., Miller E., Duska L., Oliva E. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?. Am. J. Surg. Pathol. 2012, 36:753-761.
6. Bansal N., Yendluri V., Wenham R.M. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Contr. 2009, 16:8-13.
7. Moreno-Bueno G., Hardisson D., Sanchez C., Sarrio D., Cassia R., Garcia-Rostan G., Prat J., Guo M., Herman J.G., Matias-Guiu X., Esteller M., Palacios J. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 2002, 21:7981-7990.
8. MacDonald N.D., Salvesen H.B., Ryan A., Iversen O.E., Akslen L.A., Jacobs I.J. Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Res. 2000, 60:1750-1752.
9. Albanito L., Sisci D., Aquila S., Brunelli E., Vivacqua A., Madeo A., Lappano R., Pandey D.P., Picard D., Mauro L., Ando S., Maggiolini M. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology 2008, 149:3799-3808.
10. Ahola T.M., Manninen T., Alkio N., Ylikomi T. G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Endocrinology 2002, 143:3376-3384.
11. Recchia A.G., De Francesco E.M., Vivacqua A., Sisci D., Panno M.L., Ando S., Maggiolini M. The G protein-coupled receptor 30 is up-regulated by hypoxia-inducible factor-1alpha (HIF-1alpha) in breast cancer cells and cardiomyocytes. J. Biol. Chem. 2011, 286:10773-10782.
12. Ariazi E.A., Brailoiu E., Yerrum S., Shupp H.A., Slifker M.J., Cunliffe H.E., Black M.A., Donato A.L., Arterburn J.B., Oprea T.I., Prossnitz E.R., Dun N.J., Jordan V.C. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res. 2010, 70:1184-1194.
13. Du G.Q., Zhou L., Chen X.Y., Wan X.P., He Y.Y. The G protein-coupled receptor GPR30 mediates the proliferative and invasive effects induced by hydroxytamoxifen in endometrial cancer cells. Biochem. Biophys. Res. Commun. 2012, 420:343-349.
14. Smith H.O., Arias-Pulido H., Kuo D.Y., Howard T., Qualls C.R., Lee S.J., Verschraegen C.F., Hathaway H.J., Joste N.E., Prossnitz E.R. GPR30 predicts poor survival for ovarian cancer. Gynecol. Oncol. 2009, 114:465-471.
15. Yu X., Filardo E.J., Shaikh Z.A. The membrane estrogen receptor GPR30 mediates cadmium-induced proliferation of breast cancer cells. Toxicol. Appl. Pharmacol. 2009, 245:83-90.
16. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., Prossnitz E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 307:1625-1630.
17. Smith H.O., Leslie K.K., Singh M., Qualls C.R., Revankar C.M., Joste N.E., Prossnitz E.R. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am. J. Obstet. Gynecol. 2007, 196:386 e1-9. (discussion 386 e9-11).
18. Wei Y., Zhang Z., Liao H., Wu L., Wu X., Zhou D., Xi X., Zhu Y., Feng Y. Nuclear estrogen receptor-mediated Notch signaling and GPR30-mediated PI3K/AKT signaling in the regulation of endometrial cancer cell proliferation. Oncol. Rep. 2012, 27:504-510.
19. Hori T., Kato S., Saeki M., DeMartino G.N., Slaughter C.A., Takeuchi J., Toh-e A., Tanaka K. CDNA cloning and functional analysis of p28 (Nas6p) and p40.5 (Nas7p), two novel regulatory subunits of the 26S proteasome. Gene 1998, 216:113-122.
20. Yuan C., Li J., Mahajan A., Poi M.J., Byeon I.J., Tsai M.D. Solution structure of the human oncogenic protein gankyrin containing seven ankyrin repeats and analysis of its structure-function relationship. Biochemistry 2004, 43:12152-12161.
21. Umemura A., Itoh Y., Itoh K., Yamaguchi K., Nakajima T., Higashitsuji H., Onoue H., Fukumoto M., Okanoue T., Fujita J. Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma. Hepatology 2008, 47:493-502.
22. Ortiz C.M., Ito T., Tanaka E., Tsunoda S., Nagayama S., Sakai Y., Higashitsuji H., Fujita J., Shimada Y. Gankyrin oncoprotein overexpression as a critical factor for tumor growth in human esophageal squamous cell carcinoma and its clinical significance. Int. J. Cancer 2008, 122:325-332.
23. Tang S., Yang G., Meng Y., Du R., Li X., Fan R., Zhao L., Bi Q., Jin J., Gao L., Zhang L., Li H., Fan M., Wang Y., Wu K., Liu J., Fan D. Overexpression of a novel gene gankyrin correlates with the malignant phenotype of colorectal cancer. Cancer Biol. Ther. 2010, 9:88-95.
24. Dawson S., Higashitsuji H., Wilkinson A.J., Fujita J., Mayer R.J. Gankyrin: a new oncoprotein and regulator of pRb and p53. Trends Cell Biol. 2006, 16:229-233.
25. Man J.H., Liang B., Gu Y.X., Zhou T., Li A.L., Li T., Jin B.F., Bai B., Zhang H.Y., Zhang W.N., Li W.H., Gong W.L., Li H.Y., Zhang X.M. Gankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells. J. Clin. Invest. 2010, 120:2829-2841.
26. Zhang Z., Zhou D., Lai Y., Liu Y., Tao X., Wang Q., Zhao G., Gu H., Liao H., Zhu Y., Xi X., Feng Y. Estrogen induces endometrial cancer cell proliferation and invasion by regulating the fat mass and obesity-associated gene via PI3K/AKT and MAPK signaling pathways. Cancer Lett. 2012, 319:89-97.
27. Hecht J.L., Mutter G.L. Molecular and pathologic aspects of endometrial carcinogenesis. J. Clin. Oncol. 2006, 24:4783-4791.
28. Lacey J.V., Mutter G.L., Ronnett B.M., Ioffe O.B., Duggan M.A., Rush B.B., Glass A.G., Richesson D.A., Chatterjee N., Langholz B., Sherman M.E. PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res. 2008, 68:6014-6020.
29. Daikoku T., Hirota Y., Tranguch S., Joshi A.R., DeMayo F.J., Lydon J.P., Ellenson L.H., Dey S.K. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res. 2008, 68:5619-5627.
30. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
31. Dinulescu D.M., Ince T.A., Quade B.J., Shafer S.A., Crowley D., Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat. Med. 2005, 11:63-70.
32. Moe-Behrens G.H., Klinger F.G., Eskild W., Grotmol T., Haugen T.B., De Felici M. Akt/PTEN signaling mediates estrogen-dependent proliferation of primordial germ cells in vitro. Mol. Endocrinol. 2003, 17:2630-2638.
33. Smith J.A., Zhang R., Varma A.K., Das A., Ray S.K., Banik N.L. Estrogen partially down-regulates PTEN to prevent apoptosis in VSC4.1 motoneurons following exposure to IFN-gamma. Brain Res. 2009, 1301:163-170.
34. Luo X., Chen L., Dai J., Gao Y., Wang H., Wang N., Zhao Y., Liu F., Sang Z., Wang J., Li W., He K., Jin B., Man J., Zhang W., Xia Q. Gankyrin gene deletion followed by proteomic analysis: insight into the roles of Gankyrin in tumorigenesis and metastasis. BMC Med. Genom. 2012, 5:36.
35. Meng Y., He L., Guo X., Tang S., Zhao X., Du R., Jin J., Bi Q., Li H., Nie Y., Liu J., Fan D. Gankyrin promotes the proliferation of human pancreatic cancer. Cancer Lett. 2010, 297:9-17.
36. Macaluso M., Montanari M., Cinti C., Giordano A. Modulation of cell cycle components by epigenetic and genetic events. Semin Oncol. 2005, 32:452-457.
37. Higashitsuji H., Higashitsuji H., Itoh K., Sakurai T., Nagao T., Sumitomo Y., Masuda T., Dawson S., Shimada Y., Mayer R.J., Fujita J. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 2005, 8:75-87.
38. X. Fu, D. Tan, Z. Hou, Z. Hu, G. Liu, Y. Ouyang, F. Liu, The Effect of miR-338-3p on HBx Deletion-Mutant (HBx-d382) Mediated Liver-Cell Proliferation through CyclinD1 Regulation, PLoS One. 7 e43204.
39. Jiang Q., Zhang H., Zhang P. ShRNA-mediated gene silencing of MTA1 influenced on protein expression of ER alpha, MMP-9, CyclinD1 and invasiveness, proliferation in breast cancer cell lines MDA-MB-231 and MCF-7 in vitro. J. Exp. Clin. Cancer Res. 2011, 30:60.
40. Li X., Hao Z., Fan R., Zou X., Jin H., Pan Y., He L., Du R., Gao L., Liu D., Fan D. CIAPIN1 inhibits gastric cancer cell proliferation and cell cycle progression by downregulating CyclinD1 and upregulating P27. Cancer Biol. Ther. 2007, 6:1539-1545.
41. Wang X., Zou S. The relationship of CyclinD1 and estrogen receptor expression in the process of proliferation and metastasis in breast neoplasm. J. Tongji Med. Univ. 2001, 21:231-232.
42. Revankar C.M., Mitchell H.D., Field A.S., Burai R., Corona C., Ramesh C., Sklar L.A., Arterburn J.B., Prossnitz E.R. Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem. Biol. 2007, 2:536-544.
43. He Y.Y., Cai B., Yang Y.X., Liu X.L., Wan X.P. Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Sci. 2009, 100:1051-1061.